专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008132568A3 FUSION PROTEINS BINDING TO GROWTH FACTORS 审中-公开
公开(公告)号：WO2008132568A3
公开(公告)日：2008-11-06
申请号：PCT/IB2008/000901
申请日：2008-02-27
申请人： GENEXEL-SEIN INC. , KIM, Hak-Zoo , KOH, Young, Jun , KIM, Ho-Min , JUNG, Keehoon , JEON, Choonjoo , KOH, Gou, Young
发明人： KIM, Hak-Zoo , KOH, Young, Jun , KIM, Ho-Min , JUNG, Keehoon , JEON, Choonjoo , KOH, Gou, Young
IPC分类号： C12N15/62 , C07K14/71 , C07K14/715 , A61K38/16 , A61P35/00 , A61P27/02 , A61P29/00 , A61P9/10
摘要： The present application discloses an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding two different growth factors polypeptide components. Such a polypeptide is capable of synchronously binding VEGF polypeptide and Angiopoietin polypeptide.

2. 发明申请

WO2009031044A3 AMPK DEFICIENT ANIMALS, SCREENING METHODS, AND RELATED THERAPEUTICS AND DIAGNOSTICS 审中-公开
标题翻译： AMPK缺乏动物，筛选方法及相关治疗方法及诊断
公开(公告)号：WO2009031044A3
公开(公告)日：2009-09-17
申请号：PCT/IB2008003088
申请日：2008-04-25
申请人： GENEXEL SEIN INC , KOREA ADVANCED INST SCI & TECH , CHUNG JONGKYEONG
发明人： CHUNG JONGKYEONG
IPC分类号： C12N5/06 , A01K67/033 , C12Q1/42
CPC分类号： A61K31/70 , A01K67/0339 , A01K2217/075 , A01K2227/706 , A01K2267/03 , A01K2267/0331 , A01K2267/0362 , C07K14/43581 , C12N15/8509 , G01N33/5085 , G01N2333/9121
摘要： The invention provides transgenic animal embryos comprising in the germ cells an adenosine monophosphate-activated protein kinase (AMPK) null mutation. The transgenic animal embryos are useful in screening drug candidates for treatment of a disease, such as cancer, kidney disease, diabetes, intestinal disease and obesity. The invention further provides methods for detecting disease in a tissue, comprising detecting a change in AMPK activity in the tissue compared to a control tissue. Also provided are methods for reducing symptoms of a disease in a subject, comprising administering to the subject a therapeutic amount of a drug that changes AMPK activity.
摘要翻译：本发明提供了在生殖细胞中包含腺苷一磷酸激活蛋白激酶（AMPK）无效突变的转基因动物胚胎。转基因动物胚胎可用于筛选候选药物治疗疾病，如癌症，肾脏疾病，糖尿病，肠道疾病和肥胖症。本发明还提供了用于检测组织中疾病的方法，其包括检测与对照组织相比在组织中AMPK活性的变化。还提供了减少受试者疾病症状的方法，其包括向受试者施用治疗量的改变AMPK活性的药物。

3. 发明申请

WO2007135570A8 PINK1 DEFICIENT ANIMALS, SCREENING METHODS, AND RELATED THERAPEUTICS 审中-公开
标题翻译： PINK1缺乏动物，筛选方法和相关治疗
公开(公告)号：WO2007135570A8
公开(公告)日：2008-06-05
申请号：PCT/IB2007002527
申请日：2007-04-18
申请人： GENEXEL SEIN INC , CHUNG JONGKYEONG
发明人： CHUNG JONGKYEONG
IPC分类号： A61K48/00 , C12N15/63
CPC分类号： G01N33/5088 , A01K67/0339 , A01K2217/075 , A01K2227/706 , A01K2267/0318 , G01N33/502 , G01N33/5026 , G01N33/6896 , G01N2800/2835
摘要： The present invention provides PINK1 deficient animals, screening methods, and related therapeutics. In particular, the present invention provides transgenic animals with a disruption in their endogenous PINK1 gene causing the cells in the animal to exhibit a mitochondrial related dysfunction phenotype and/or causing the animal to exhibit symptoms of neurodegenerative disease. The present invention also provides methods of using PINK1 deficient cells or animals to screen candidate compounds, as well as therapeutics agents useful for treating PINK1 deficient subjects.
摘要翻译：本发明提供了PINK1缺陷型动物，筛选方法和相关疗法。特别地，本发明提供转基因动物，其内源性PINK1基因破坏，导致动物细胞表现出线粒体相关功能障碍表型和/或使动物表现出神经变性疾病的症状。本发明还提供使用PINK1缺陷细胞或动物来筛选候选化合物的方法，以及可用于治疗PINK1缺乏受试者的治疗剂。

4. 发明申请

WO2007132292A2 THERAPY FOR ALZHEIMER'S DISEASE 审中-公开
标题翻译：治疗阿尔茨海默病
公开(公告)号：WO2007132292A2
公开(公告)日：2007-11-22
申请号：PCT/IB2006/004117
申请日：2006-08-02
申请人： GENEXEL-SEIN, INC. , KIM, Jaeseob , BAE, Eunkyung , KIM, Jungmo
发明人： KIM, Jaeseob , BAE, Eunkyung , KIM, Jungmo
CPC分类号： A61K31/663 , A61K31/675 , C12N15/1137 , C12N2310/11 , C12N2310/111 , C12Y205/0101
摘要： The present invention relates to newly identified methods and compositions for modulating the cellular processing of beta-amyloid precursor protein ("APP") and for the prevention or treatment of diseases associated with abnormal APP processing, such as Alzheimer's disease ("AD"). The invention also relates the identification of molecular pathways heretofore unknown to be involved in APP processing. The invention also relates to the prevention or treatment of AD disease symptoms using medicaments that modify the activity of novel molecular targets involved in APP processing.
摘要翻译：本发明涉及用于调节β-淀粉样蛋白前体蛋白（“APP”）的细胞加工和用于预防或治疗与异常APP加工相关的疾病如阿尔茨海默病（“AD”）的新鉴定的方法和组合物。本发明还涉及迄今未知涉及APP处理的分子途径的鉴定。本发明还涉及使用改变APP处理涉及的新型分子靶的活性的药物来预防或治疗AD疾病症状。

5. 发明申请

WO2009031818A3 BIOMARKER FOR PURIFICATION OR IDENTIFICATION OF MESENCHYMAL STEM CELLS AND METHODS OF PURIFICATION OF MESENCHYMAL STEM CELLS BY USING IT 审中-公开
标题翻译：用于纯化间质干细胞的纯化或鉴定的生物标记以及使用它们纯化间充质干细胞的方法
公开(公告)号：WO2009031818A3
公开(公告)日：2009-04-23
申请号：PCT/KR2008005191
申请日：2008-09-03
申请人： GENEXEL SEIN INC , BAE SOHYUN , KIM HOEON
发明人： BAE SOHYUN , KIM HOEON
IPC分类号： C07K16/18 , C12N5/0775
CPC分类号： C07K16/40 , C12N5/0663 , C12N5/0665 , C12N5/0667
摘要： The present invention is related to biomarker for purification and idem i fi cat ion of mesenchymal stem cells and methods for purif ication of imseiich\mai stem cells by using it. The present invention provides composition, apparatus and kit for separation or identification of MSCs comprising anti -fibroblast activation protein a (FAP a ). Also, the present invention provides the method for identification and purification of MSCs. In detail, the present invention provides the method for identification of MSCs comprising the steps of : contacting anti -FAP a antibody with test cell; detecting the forming of antigen-antibody complex of FAP a of the above test cell and the above anti -FAP a antibody. And the present invention provides the method for separation and purification MSCs comprising the steps of : forming antigen-antibody complex by contacting liquid biological media having MSC with anti-FAP a antibody; and collecting the above antigen-antibody complex.
摘要翻译：本发明涉及用于间充质干细胞的纯化和同种化的生物标志物和通过使用它来纯化干细胞的干细胞的方法。本发明提供了用于分离或鉴定包含抗成纤维细胞活化蛋白a（FAP a）的MSC的组合物，设备和试剂盒。而且，本发明提供了用于鉴定和纯化MSC的方法。具体而言，本发明提供了用于鉴定MSC的方法，其包括以下步骤：使抗-FAPα抗体与测试细胞接触; 检测上述测试细胞的FAP a和上述抗-FAPα抗体的抗原 - 抗体复合物的形成。并且本发明提供了用于分离和纯化MSCs的方法，其包括以下步骤：通过使具有MSC的液体生物培养基与抗-FAPα抗体接触形成抗原 - 抗体复合物; 并收集上述抗原 - 抗体复合物。

6. 发明申请

WO2009031044A2 AMPK DEFICIENT ANIMALS, SCREENING METHODS, AND RELATED THERAPEUTICS AND DIAGNOSTICS 审中-公开
标题翻译： AMPK缺陷型动物，筛查方法及相关治疗和诊断
公开(公告)号：WO2009031044A2
公开(公告)日：2009-03-12
申请号：PCT/IB2008/003088
申请日：2008-04-25
申请人： GENEXEL-SEIN, INC. , KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY , CHUNG, Jongkyeong
发明人： CHUNG, Jongkyeong
CPC分类号： A61K31/70 , A01K67/0339 , A01K2217/075 , A01K2227/706 , A01K2267/03 , A01K2267/0331 , A01K2267/0362 , C07K14/43581 , C12N15/8509 , G01N33/5085 , G01N2333/9121 , Y02A50/481
摘要： The invention provides transgenic animal embryos comprising in the germ cells an adenosine monophosphate-activated protein kinase (AMPK) null mutation. The transgenic animal embryos are useful in screening drug candidates for treatment of a disease, such as cancer, kidney disease, diabetes, intestinal disease and obesity. The invention further provides methods for detecting disease in a tissue, comprising detecting a change in AMPK activity in the tissue compared to a control tissue. Also provided are methods for reducing symptoms of a disease in a subject, comprising administering to the subject a therapeutic amount of a drug that changes AMPK activity.
摘要翻译：本发明提供了在生殖细胞中包含腺苷一磷酸激活的蛋白激酶（AMPK）无效突变的转基因动物胚胎。转基因动物胚胎可用于筛选用于治疗疾病（例如癌症，肾脏疾病，糖尿病，肠道疾病和肥胖症）的候选药物。本发明进一步提供了用于检测组织中的疾病的方法，包括检测组织中与对照组织相比AMPK活性的变化。还提供了用于减轻受试者中疾病症状的方法，包括给受试者施用治疗量的改变AMPK活性的药物。

7. 发明申请

WO2007135570A2 PINK1 DEFICIENT ANIMALS, SCREENING METHODS, AND RELATED THERAPEUTICS 审中-公开
标题翻译： PINK1缺乏动物，筛选方法和相关治疗
公开(公告)号：WO2007135570A2
公开(公告)日：2007-11-29
申请号：PCT/IB2007/002527
申请日：2007-04-18
申请人： GENEXEL-SEIN, INC. , CHUNG, Jongkyeong
发明人： CHUNG, Jongkyeong
CPC分类号： G01N33/5088 , A01K67/0339 , A01K2217/075 , A01K2227/706 , A01K2267/0318 , G01N33/502 , G01N33/5026 , G01N33/6896 , G01N2800/2835
摘要： The present invention provides PINK1 deficient animals, screening methods, and related therapeutics. In particular, the present invention provides transgenic animals with a disruption in their endogenous PINK1 gene causing the cells in the animal to exhibit a mitochondrial related dysfunction phenotype and/or causing the animal to exhibit symptoms of neurodegenerative disease. The present invention also provides methods of using PINK1 deficient cells or animals to screen candidate compounds, as well as therapeutics agents useful for treating PINK1 deficient subjects.
摘要翻译：本发明提供了PINK1缺陷型动物，筛选方法和相关疗法。特别地，本发明提供转基因动物，其内源性PINK1基因破坏，导致动物细胞表现出线粒体相关功能障碍表型和/或使动物表现出神经变性疾病的症状。本发明还提供使用PINK1缺陷细胞或动物来筛选候选化合物的方法，以及可用于治疗PINK1缺乏受试者的治疗剂。

8. 发明申请

WO2007135570A3 PINK1 DEFICIENT ANIMALS, SCREENING METHODS, AND RELATED THERAPEUTICS 审中-公开
标题翻译： PINK1缺陷型动物，筛查方法和相关治疗
公开(公告)号：WO2007135570A3
公开(公告)日：2008-03-27
申请号：PCT/IB2007002527
申请日：2007-04-18
申请人： GENEXEL SEIN INC , CHUNG JONGKYEONG
发明人： CHUNG JONGKYEONG
IPC分类号： G01N33/50 , A01K67/033 , A61K48/00
CPC分类号： G01N33/5088 , A01K67/0339 , A01K2217/075 , A01K2227/706 , A01K2267/0318 , G01N33/502 , G01N33/5026 , G01N33/6896 , G01N2800/2835
摘要： The present invention provides PINK1 deficient animals, screening methods, and related therapeutics. In particular, the present invention provides transgenic animals with a disruption in their endogenous PINK1 gene causing the cells in the animal to exhibit a mitochondrial related dysfunction phenotype and/or causing the animal to exhibit symptoms of neurodegenerative disease. The present invention also provides methods of using PINK1 deficient cells or animals to screen candidate compounds, as well as therapeutics agents useful for treating PINK1 deficient subjects.
摘要翻译：本发明提供了PINK1缺陷动物，筛选方法和相关治疗剂。具体而言，本发明提供了内源性PINK1基因破坏的转基因动物，其导致动物中的细胞表现出线粒体相关功能障碍表型和/或导致动物表现出神经退行性疾病的症状。本发明还提供使用PINK1缺陷细胞或动物筛选候选化合物的方法，以及用于治疗PINK1缺陷受试者的治疗剂。

9. 发明申请

WO2007123562A3 ANTHRAX THERAPIES, COMPOSITIONS, AND METHODS RELATED THERETO 审中-公开
公开(公告)号：WO2007123562A3
公开(公告)日：2007-11-01
申请号：PCT/US2006/028147
申请日：2006-07-21
申请人： GENEXEL-SEIN, INC. , INN, Kyung-Soo , HONG, Hyo Jeong , LIM, Nam-Kyu , LEE, Sangyoon
发明人： INN, Kyung-Soo , HONG, Hyo Jeong , LIM, Nam-Kyu , LEE, Sangyoon
IPC分类号： C07K16/12
摘要： The present invention relates to molecules that complex with Bacillus anthracis protective antigen. Ih some embodiments, the invention relates to a composition for neutralizing anthrax toxin comprising an antibody and the use of said antibody as a medicament. In further embodiments, the invention relates to detecting Bacillus anthracis in a subject. The present invention is also concerned with a composition having a synergistic effect on anthrax toxin neutralization, comprising a protective antigen-specific antibody and a lethal factor-specific antibody.

10. 发明申请

WO2007123562A2 ANTHRAX THERAPIES, COMPOSITIONS, AND METHODS RELATED THERETO 审中-公开
标题翻译： ANTHRAX治疗，组合物和方法相关
公开(公告)号：WO2007123562A2
公开(公告)日：2007-11-01
申请号：PCT/US2006028147
申请日：2006-07-21
申请人： GENEXEL SEIN INC , INN KYUNG-SOO , HONG HYO JEONG , LIM NAM-KYU , LEE SANGYOON
发明人： INN KYUNG-SOO , HONG HYO JEONG , LIM NAM-KYU , LEE SANGYOON
IPC分类号： A61K39/39
CPC分类号： C07K16/1278 , A61K2039/505 , C07K2317/34 , C07K2317/76
摘要： The present invention relates to molecules that complex with Bacillus anthracis protective antigen. Ih some embodiments, the invention relates to a composition for neutralizing anthrax toxin comprising an antibody and the use of said antibody as a medicament. In further embodiments, the invention relates to detecting Bacillus anthracis in a subject. The present invention is also concerned with a composition having a synergistic effect on anthrax toxin neutralization, comprising a protective antigen-specific antibody and a lethal factor-specific antibody.
摘要翻译：本发明涉及与炭疽芽孢杆菌保护性抗原复合的分子。在一些实施方案中，本发明涉及用于中和包含抗体的炭疽毒素的组合物和所述抗体作为药物的用途。在进一步的实施方案中，本发明涉及检测受试者中的炭疽芽孢杆菌。本发明还涉及对炭疽毒素中和具有协同作用的组合物，其包含保护性抗原特异性抗体和致死因子特异性抗体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式